

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
022/0149	Pharmacia Limited	Macrodex in Normal Saline	Dextran 70 30 g	or trauma in which circulatory volume deficit is present. Also for prophylaxis of venous thrombosis and pulmonary embolism in patients at moderate or high risk of thromboembolism. POM See PL/0022/0148.	15th January 1994
022/0153	Pharmacia Limited	Salazopyrin Desensitisation Kit	1 mg Capsule: Sulfasalazine USP 10 mg Capsule: Sulfasalazine USP 10-0 mg 100 mg Capsule: Sulfasalazine USP 100-0 mg	For the relief of intolerance of sulphasalazine as manifested as fever and/or rash. POM	15th January 1994
022/0155	Pharmacia Limited	Salazopyrin En-Taba	Sulphasalazine USP 0.5 mg	Induction and maintenance of remission of ulcerative colitis; treatment of active Crohn's Disease; treatment of rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (NSAIDs). POM	15th January 1994
0022/0156	Pharmacia Limited	Salazopyrin Suppositories	Sulphasalazine USP 0.5 g	Ulcerative colitis or Crohn's Disease affecting the rectum. POM	15th January 1994
0022/0157	Pharmacia Limited	Salazopyrin Suspension	Sulphasalazine USP 250.0 mg/5 ml	Induction and maintenance of remission of ulcerative colitis and treatment of active Crohn's Disease. POM	15th January 1994
0022/0158	Pharmacia Limited	Salazopyrin Tablets	Sulphasalazine* USP 0.5 gm *Coated with about 3% POVIDONE, and containing not more than 5% moisture. Weight of coated material used is approx 535 mg	See PL/0022/0157.	15th January 1994
0031/0335	Roche Products Limited	Pulmozyme Inhalation Solution 1000 u/ml (fmg/ml)	Composition per ampoule: Recombinant Human Deoxyribonuclease 1 (rhDNase, Dornase alfa pINN) HSE 2500 U (equivalent to 2.5 mg)	Daily administration is indicated in the management of cystic fibrosis patients with an FVC of greater than 40% of predicted and over 5 years of age to improve pulmonary function. POM	12th January 1994
0039/0435	Evans Medical Limited	BCG Vaccine Intradermal	BCG (Copenhagen Sub-Strain 1077) 8.0 × 10 ⁸ vu* to 26.0 × 10 ⁶ vu* * viable units per ml	Intradermal BCG Vaccine induces active immunity to tuberculosis. Vaccinated persons normally become mantoux-positive after eight weeks but sometimes up to 14 weeks are needed. POM	6th January 1994
0039/0436	Evans Medical Limited	BCG Vaccine Percutaneous	BCG (Copenhagen Sub-Strain 1077) 50.0 × 10 ⁶ vu* to 250 × 10 ⁶ vu* * viable units per vial	Percutaneous BCG vaccine induces active immunity to tuberculosis. Vaccinated persons normally become mantoux-positive after eight weeks, but sometimes up to 14 weeks are needed. POM	25th January 1994
0039/0437	Evans Medical Limited	BCG Vaccine Intradermal Isoniazid Resistant	BCG (Isoniazid Resistant Sub strain) 8.0 × 10 ⁸ vu* to 26.0 × 10 ⁶ vu* * viable units per ml.	Isoniazid Resistant Intradermal BCG Vaccine is suitable for vaccinating tuberculosis contacts while they are receiving prophylactic treatment with isoniazid. POM	6th January 1994
0039/0438	Evans Medical Limited	Mevilin-L Measles Vaccine Live	Live Measles Virus of the Schwarz Strain at a concentration of not less than 10 ³ PFU Per Dose (0.5 ml)	Prophylaxis against measles and if given within 72 hours of contact, to prevent development of infection. POM	6th January 1994
0039/0443	Evans Medical Limited	Control Solution for Mantoux Test	None	As a control for the Mantoux Test. POM	28th January 1994
0039/0444	Evans Medical Limited, Evans House, Regent Park, Kingston Road, Leatherhead, Surrey, KT22 7PQ	Adsorbed Tetanus Vaccine BP	Each 0.5ml dose contains Tetanus Toxoid not less than HSE ≥ 40.00 IU adsorbed onto aluminium hydroxide	To provide active immunisation against Tetanus and reinforcement of immunity to Tetanus. POM	28th January 1994
0086/0179	Hoechst UK Limited	Begrivac	Split Influenza Virus Vaccine BP containing antigens from:— Singapore 6/86 — LIKE HA* WHO 15 UG Beijing 353/89 — LIKE HA* WHO 15 UG Yamagata 16/88 — LIKE HA* WHO 15 UG *HA — haemagglutinin	Active immunisation against influenza. POM	28th January 1994
0142/0379	A. H. Cox and Company (v/a Cox Pharmaceuticals)	Isosorbide Mononitrate Tablets 20 mg	Isosorbide Mononitrate* HSE 20.00 mg *(Incorporated as a 40% dilution in Lactose)	Prophylaxis of angina pectoris, adjunctive treatment in the management of severe acute or chronic congestive cardiac failure not responding to cardiac glycosides and/or diuretics. PM	30th March 1994
0173/0149	Diomed Developments Limited (v/a Dermal Laboratories)	Betamethasone Valerate Scalp Application BP	Betamethasone Valerate BP 0.12% w/w (Equivalent to Betamethasone 0.1% w/w)	For the treatment of dermatoses of the scalp, such as psoriasis and seborrhoeic dermatitis, which are unresponsive to less potent corticosteroids. POM	13th January 1994
0201/0177	Schering-Plough Limited	Uni-Dur Sustained Release Tablets 400 mg	Theophylline Anhydrous EP 400 mg	For relief and prevention of symptoms of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema in adults and children over 12 years of age.	13th January 1994